Source: Form 10-K Annual Report for the Fiscal Year Ended December 31, 2025
Table of Contents
- 1. Quick Facts / Company Snapshot
- 2. Company Overview
- 3. Business Segments
- 4. History and Evolution
- 5. Products and Services
- 6. Brand Portfolio
- 7. Geographical Presence
- 8. Board of Directors and Leadership Team
- 9. Future Strategy
- 10. Key Strengths
- 11. Key Challenges and Risks
- 12. Conclusion and Strategic Outlook
- 13. Official Site
- 14. Income Statement
- 15. Balance sheet
- 16. Cash flow
- 17. Subsidiaries & Joint Ventures
- 18. Other Investments & Holdings
- 19. Physical properties
- 20. Investments and capital expenditure
- 21. Shareholding pattern / Ownership
- 22. Frequently Asked Questions
Quick Facts / Company Snapshot
| Attribute | Details |
|---|---|
| Company Legal Name | Treace Medical Concepts, Inc. |
| Ticker Symbol & Exchange | NASDAQ: TMCI |
| Incorporation Jurisdiction | Delaware, United States |
| Founding Year | 2013 |
| Headquarters Location | Ponte Vedra, Florida, United States |
| Founder & Chief Executive Officer | John T. Treace |
| Chief Financial Officer | Mark L. Hair |
| Industry Sector | Medical Devices / Orthopedics (Foot & Ankle) |
| Primary Flagship Product | Lapiplasty® 3D Bunion Correction® System |
| Full-Time Employees | Approximately 450 (as of December 31, 2025) |
| FY2025 Total Revenue | $212,690 thousand USD |
Company Overview
Treace Medical Concepts, Inc. (NASDAQ: TMCI) is a commercial-stage medical technology company dedicated to advancing the standard of care for the surgical management of bunion and related midfoot deformities. Hallux Valgus (commonly known as a bunion) is a painful, disfiguring 3-dimensional deformity originating from an unstable joint in the middle of the foot. Bunions affect approximately 67 million Americans, with an estimated 1.1 million patients becoming annual surgical candidates, representing a potential total addressable market opportunity exceeding $5 billion in the United States.
The company pioneered and patented the Lapiplasty® 3D Bunion Correction® System, a proprietary procedural solution comprising specialized instruments, single-use titanium implants, and advanced surgical methods. Unlike traditional 2D osteotomy procedures that shave off the bony bump or cut the metatarsal bone in half, the Lapiplasty® System rotates the entire metatarsal bone back into physical alignment across all three anatomical planes (horizontal, vertical, and rotational) while permanently fusing the underlying unstable tarsometatarsal (TMT) joint. Treace Medical Concepts has expanded its product footprint from a single-procedure focus into a comprehensive bunion solutions provider, offering systems for midfoot deformities, minimally invasive metatarsal osteotomies, great toe fusions, and patient-specific surgical instrumentation.
Business Segments
Treace Medical Concepts, Inc. operates as a single reportable business segment focused on the design, manufacture, and marketing of medical devices for foot and ankle surgical procedures. The company’s chief operating decision maker (CODM) evaluates financial performance and allocates corporate resources on an entity-wide basis.
- Primary Surgical Product Revenue: Driven by single-use sterile implant kits, procedure-specific reusable instrumentation trays, digital preoperative planning solutions, and specialized hand instruments used across hospital outpatient and ambulatory surgery center (ASC) settings. Net sales reached $212,690 thousand in FY2025, compared to $209,357 thousand in FY2024 and $187,118 thousand in FY2023.
- Commercial Sales Distribution Channels: Products are distributed within the United States via a direct employee sales force, independent sales agency representatives, and stocking distributors. In FY2025, direct employee sales representatives generated approximately 80% of total company revenue, while sales to stocking distributors accounted for $13,000 thousand.
History and Evolution
Treace Medical Concepts was originally formed as a medical device consulting business in July 2013 and pivoted to focus exclusively on the foot and ankle market in January
2014. The company received initial 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its flagship Lapiplasty® System in March 2015 and commenced commercial launch shortly thereafter.
Key milestone events in the company’s organizational evolution include:
- 2018: The company’s Surgeon Advisory Board published a seminal peer-reviewed paper defining four distinct anatomical classes of bunion deformities, shaping Treace’s long-term product development roadmap.
- April 2021: Completed its Initial Public Offering (IPO) on the Nasdaq Global Select Market under the symbol “TMCI”, generating net proceeds of $107.6 million.
- Late 2021: Launched the Adductoplasty® Midfoot Correction System to treat midfoot deformities and metatarsus adductus in conjunction with bunion repair.
- February 2023: Closed a follow-on public equity offering raising $107.5 million in net proceeds to expand direct sales infrastructure and commercial initiatives.
- June 2023: Acquired specific assets of MIOS Marketing, LLC d/b/a RedPoint Medical3D (RPM-3D), incorporating patient-specific 3D CT pre-operative planning software and 3D-printed cut guide technologies (IntelliGuide®) into its portfolio.
- Late 2023 – 2024: Commercialized the SpeedPlate® Rapid Compression Implant platform and introduced specialized solutions covering all four bunion classes, including the Micro-Lapiplasty® System, Mini-Adductoplasty™ Guides, Nanoplasty® 3D Minimally Invasive System, Percuplasty™ Percutaneous 3D System, and SpeedMTP® System.
- December 2025: Refinanced existing credit facilities by securing a $175.0 million senior debt facility with SLR Investment Corp. and affiliates, borrowing $60.0 million under tranche one at closing to retire previous term and revolving debt.
Products and Services
Treace Medical Concepts provides a broad range of surgical systems, titanium fixation implants, sterile single-use instrumentation, and digital surgical planning technologies:
- 3D Bunion Correction Systems: The Lapiplasty® 3D Bunion Correction® System, Micro-Lapiplasty® System (utilizing 2 cm small incisions), and next-generation Lapiplasty Lightning™ platform. These systems feature procedure-specific tools like the Lapiplasty® Positioner, Compressor, and 3-n-1® Guide alongside biplanar titanium plating kits.
- Minimally Invasive Metatarsal Osteotomy Systems: The Nanoplasty® 3D Minimally Invasive Bunion Correction System (utilizing a titanium intramedullary implant with locking screws via a 1.5 cm side incision) and the Percuplasty™ Percutaneous 3D Bunion Correction® System (designed for percutaneous “poke-hole” incisions supported by the Percuplasty™ MIS Power System).
- Midfoot & Joint Fusion Platforms: The Adductoplasty® Midfoot Correction System and Mini-Adductoplasty™ Guides (4 cm incision) for second and third TMT joint fusions, alongside the SpeedMTP® System designed for first metatarsophalangeal (MTP) joint fusions.
- Fixation & Compression Implant Technologies: The SpeedPlate® Rapid Compression Implant platform, including specialized variants such as the SpeedPlate® Micro-Quad implant, SpeedAkin™ Anatomic Compression Implant, and SpeedTMT™ Rapid Compression Implant.
- Patient-Specific Instrumentation (PSI): The IntelliGuide® System, which converts patient CT scan data into custom 3D pre-operative plans and 3D-printed patient-specific cut guides for Lapiplasty® and Adductoplasty® procedures.
- Deformity Correction & Ancillary Systems: The Hammertoe PEEK Fixation System, Treace Allograft Wedges, and CortiFuse™ Flowable Cortical Fibers.
- Sterile Single-Use Surgical Instruments: Specialized hand tools including FastGrafter® Autografter Harvesting System, SpeedRelease® Guided Release Instrument, TriTome® Triple-Edge Release Instrument, RazorTome® Precision Osteotome, LapiTome® Hooked Bone Removal Osteotome, GreatRelease™ Rapid MTP Release Instrument, CornerChisel™ Release Tool, NanoRasp™ MIS Bone Contouring Tool, FeatherRasp™ Rapid Bone Contouring Instrument, and Akinator™ Single-cut Akin Wedge Osteotomy tool.
Brand Portfolio
The company maintains an intellectual property and trademark portfolio protecting its clinical solutions and brand identities:
- Registered U.S. Trademarks: Treace Medical Concepts®, Lapiplasty®, Adductoplasty®, 3D Bunion Correction®, IntelliGuide®, Nanoplasty®, SpeedMTP®, SpeedPlate®, and The Leader in Hallux Valgus Surgery®.
- Pending U.S. Trademarks: A Step Ahead™, Akinator™, BunionMasters™, Mini-Adductoplasty™, Percuplasty™, and SpeedTMT™.
Geographical Presence
Treace Medical Concepts operates exclusively within the United States market. The company does not maintain international operations or generate revenue from foreign jurisdictions, and all long-lived physical assets are held domestically.
- Corporate Headquarters: Located in Ponte Vedra, Florida, where the company leases approximately 125,000 square feet of office, research and development, training lab, and light assembly facility space under a lease expiring in July 2032.
- Commercial Sales Infrastructure: As of December 31, 2025, Treace fielded a commercial market team of 297 individuals, consisting of direct employee sales representatives, district development managers, market development managers, national accounts teams, and sales management, supplemented by independent sales agencies and selective stocking distributors.
Board of Directors and Leadership Team
The governance of Treace Medical Concepts is overseen by a Board of Directors comprised of executive leadership and independent industry veterans:
- John T. Treace: Founder, Chief Executive Officer, and Chairman of the Board
- Mark L. Hair: Chief Financial Officer
- John K. Bakewell: Independent Director
- Lance A. Berry: Independent Director
- Lawrence W. Hamilton: Independent Director
- Elizabeth S. Hanna: Independent Director
- Deepti Jain: Independent Director
- Jane E. Kiernan: Independent Director
We are a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities.
John T. Treace, Founder, Chief Executive Officer, and Chairman of the Board
Future Strategy
Treace Medical Concepts is executing a multi-faceted growth strategy focused on expanding its market share across all bunion treatment classes:
- Comprehensive Product Innovation: Advancing from a sole reliance on the Lapiplasty® system toward a broad suite of solutions addressing all four bunion classes. Planned releases for 2026 include the next-generation Lapiplasty Lightning™ platform, the SpeedTMT™ Rapid Compression Implant, and Percuplasty SuperBite™ Screws.
- Sales Channel Optimization: Transitioning sales coverage toward direct employee sales representatives in high-density patient regions while utilizing stocking distributors and independent sales agencies to optimize cost structures and market penetration.
- Surgeon Education and Training: Continuing medical education initiatives through hands-on simulated surgical workshops, online “Mastery Webinars,” and regional Bunion Masters™ educational programs designed to train podiatric and orthopedic surgeons on 3D correction procedures.
- Clinical Evidence Generation: Investing in prospective, multicenter post-market clinical trials (such as ALIGN3D, MTA3D, and SPRINT) to generate peer-reviewed data demonstrating low deformity recurrence rates (0.7% at 48 months in ALIGN3D) and rapid return to early weight-bearing (average 8.4 days).
- Targeted Patient Outreach: Maintaining direct-to-patient brand awareness campaigns and digital educational resources (including the “Find a Doctor” locator tool) while optimizing promotional spending to improve operating efficiency.
Key Strengths
- Proprietary Anatomic 3D Correction Technology: Differentiated instrumentation and titanium fixation designed to reproducibly address the root cause of bunions across all three anatomical dimensions.
- Robust Intellectual Property Estate: Portfolio holding 95 granted U.S. patents, 1 exclusively licensed U.S. patent, 39 granted foreign patents, and 189 pending global patent applications as of December 31, 2025.
- Extensive Clinical Data Portfolio: Supported by 26 peer-reviewed journal publications as of December 2025, validating low recurrence rates, minimal non-union rates, and rapid post-operative recovery timelines.
- Established Direct Sales Model: Highly specialized direct sales force generating approximately 80% of total company revenue and offering operating room support to surgeon customers.
- Active Surgeon Customer Base: Growing network of active surgeons performing procedures with Treace systems, reaching 3,337 active surgeons in FY2025 (a 6% increase year-over-year).
Key Challenges and Risks
- Macroeconomic and Consumer Pressures: Inflationary pressures, softening consumer sentiment, rising health insurance deductibles, and higher out-of-pocket costs can cause patients to defer elective surgical procedures.
- Intense Market Competition and Product Bundling: Competitors (including Stryker, Zimmer Biomet/Paragon 28, Arthrex, DePuy Synthes, and Enovis) possess broader product lines and significant market power. Certain competitors utilize contract bundling and volume rebates across unrelated product categories to induce hospital networks to restrict purchasing of Treace products.
- Shifts in Surgical Setting and Procedure Mix: Transition of elective bunion procedures from hospital outpatient departments to Ambulatory Surgery Centers (ASCs), combined with evolving surgeon preferences for lower-priced minimally invasive metatarsal osteotomies, impacts average selling prices (ASPs) and gross margins.
- Intellectual Property Litigation: Ongoing litigation, including plaintiff patent enforcement lawsuits brought by Treace against Stryker and Zimmer Biomet/Paragon 28, as well as counterclaims and administrative inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB).
- Debt Service Obligations and Covenants: Obligations under the 5-year credit facilities with SLR Investment Corp., requiring compliance with minimum liquidity thresholds ($60.0 million outstanding term loan principal) and restrictive covenants.
Conclusion and Strategic Outlook
Treace Medical Concepts, Inc. remains focused on transforming the surgical management of Hallux Valgus and related midfoot deformities. By transitioning from a single-product company centered on its original Lapiplasty® system into a comprehensive solution provider offering minimally invasive osteotomies, midfoot fusion plates, patient-specific guides, and specialized power instruments, Treace is positioned to address the full spectrum of surgeon and patient preferences. While navigating competitive market bundling, legal enforcement of its intellectual property, and macroeconomic headwinds surrounding elective surgeries, the company continues to leverage its direct sales infrastructure, expanding clinical evidence, and targeted surgeon training programs to build long-term market share.
Official Site
Official Corporate Website: https://www.treace.com
Income Statement
| Metric | 2025 ($ in thousands) | 2024 ($ in thousands) | YoY Growth (%) |
|---|---|---|---|
| Revenue | $212,690 | $209,357 | +1.59% |
| Cost of goods sold | $42,938 | $41,093 | +4.49% |
| Gross profit | $169,752 | $168,264 | +0.88% |
| Sales and marketing expense | $140,880 | $147,643 | -4.58% |
| Research and development expense | $20,282 | $20,589 | -1.49% |
| General and administrative expense | $62,744 | $55,720 | +12.61% |
| Total operating expenses | $223,906 | $223,952 | -0.02% |
| Loss from operations | $(54,154) | $(55,688) | -2.75% |
| Interest income | $2,777 | $4,877 | -43.06% |
| Interest expense | $(5,320) | $(5,256) | +1.22% |
| Debt extinguishment loss | $(2,737) | $0 | N/A |
| Other income, net | $432 | $324 | +33.33% |
| Other non-operating income (expense), net | $(4,848) | $(55) | +8714.55% |
| Net loss | $(59,002) | $(55,743) | +5.85% |
Balance sheet
| Metric | 2025 ($ in thousands) | 2024 ($ in thousands) | YoY Growth (%) |
|---|---|---|---|
| Cash and cash equivalents | $10,708 | $11,350 | -5.66% |
| Marketable securities, short-term | $37,659 | $64,327 | -41.46% |
| Accounts receivable, net | $42,155 | $40,803 | +3.31% |
| Inventories | $36,031 | $39,255 | -8.21% |
| Prepaid expenses and other current assets | $5,501 | $5,667 | -2.93% |
| Total current assets | $132,054 | $161,402 | -18.18% |
| Property and equipment, net | $29,752 | $25,953 | +14.64% |
| Intangible assets, net | $7,125 | $8,075 | -11.76% |
| Goodwill | $12,815 | $12,815 | 0.00% |
| Operating lease right-of-use assets | $7,614 | $8,442 | -9.81% |
| Other non-current assets, net | $1,221 | $407 | +200.00% |
| Total assets | $190,581 | $217,094 | -12.21% |
| Accounts payable | $6,726 | $10,522 | -36.08% |
| Accrued liabilities | $5,784 | $7,197 | -19.63% |
| Accrued commissions | $9,365 | $10,121 | -7.47% |
| Accrued compensation | $6,331 | $6,575 | -3.71% |
| Other liabilities (current) | $2,429 | $510 | +376.27% |
| Total current liabilities | $30,635 | $34,925 | -12.28% |
| Long-term debt, net | $55,583 | $53,306 | +4.27% |
| Operating lease liabilities, net of current portion | $13,982 | $15,934 | -12.25% |
| Other long-term liabilities | $3,049 | $37 | +8140.54% |
| Total liabilities | $103,249 | $104,202 | -0.91% |
| Common stock | $64 | $62 | +3.23% |
| Additional paid-in capital | $337,371 | $303,004 | +11.34% |
| Accumulated deficit | $(248,992) | $(189,990) | +31.06% |
| Accumulated other comprehensive income (loss) | $72 | $97 | -25.77% |
| Treasury stock, at cost | $(1,183) | $(281) | +321.00% |
| Total stockholders’ equity | $87,332 | $112,892 | -22.64% |
| Total liabilities and stockholders’ equity | $190,581 | $217,094 | -12.21% |
Cash flow
| Metric | 2025 ($ in thousands) | 2024 ($ in thousands) | YoY Growth (%) |
|---|---|---|---|
| Net cash provided by (used in) operating activities | $(15,970) | $(37,167) | -57.03% |
| Net cash provided by (used in) investing activities | $13,251 | $35,375 | -62.54% |
| Net cash provided by (used in) financing activities | $2,077 | $160 | +1198.12% |
| Net increase (decrease) in cash and cash equivalents | $(642) | $(1,632) | -60.66% |
| Cash and cash equivalents at beginning of period | $11,350 | $12,982 | -12.57% |
| Cash and cash equivalents at end of period | $10,708 | $11,350 | -5.66% |
Subsidiaries & Joint Ventures
- MIOS Marketing, LLC d/b/a RedPoint Medical3D (“RPM-3D”): Acquired assets integrated into the business in June 2023.
- Operating Entities: The Company operates as a single reportable segment entity in the United States and has no separate material corporate subsidiaries or joint ventures reported.
Other Investments & Holdings
- Available-for-Sale Short-Term Marketable Securities (at fair value as of December 31, 2025): $37,659 thousand total.
- U.S. treasury and government agencies: $6,718 thousand
- Corporate debt: $19,302 thousand
- Asset-backed securities: $10,438 thousand
- Yankee CD: $1,201 thousand
Physical properties
- Principal Executive Offices: 100 Palmetto Park Place, Ponte Vedra, Florida 32081 (approximately 125,000 square feet under a lease expiring July 2032).
- Subleased Facilities: Former corporate headquarter locations in Ponte Vedra, Florida subleased through lease expiration in April 2026.
Investments and capital expenditure
- Capital Expenditures (Purchases of Property and Equipment): $13,517 thousand in 2025 ($11,593 thousand in 2024).
- Capitalized surgical instruments for reusable trays: $11.6 million in 2025 ($9.5 million in 2024).
- Equipment and leasehold improvements: $1.9 million in 2025 ($2.1 million in 2024).
- Research and Development Expenditures: $20,282 thousand in 2025 ($20,589 thousand in 2024).
Shareholding pattern / Ownership
| Category | Shares (Dec 31, 2025) | % Stake (Dec 31, 2025) | Previous % Stake (Dec 31, 2024) |
|---|---|---|---|
| Officers, Directors, and Affiliates | 14,688,689 | 23.0% | Not Disclosed |
| Public and Non-Affiliate Stockholders | 49,175,176 | 77.0% | Not Disclosed |
| Total Common Stock Outstanding | 63,863,865 | 100.0% | 100.0% |
Frequently Asked Questions
What is the core technology behind the Lapiplasty® System?
The Lapiplasty® 3D Bunion Correction® System is a surgical platform comprising specialized procedural instruments and titanium implants. Unlike traditional 2D shaving or bone-cutting methods, Lapiplasty® rotates the entire deviated metatarsal bone back into normal 3D anatomical alignment and permanently secures the underlying unstable joint using biplanar titanium plates or SpeedPlate® dynamic fixation, allowing patients to bear weight early in a walking boot.
What exchange and ticker symbol does Treace Medical Concepts trade under?
Treace Medical Concepts, Inc. trades publicly on the Nasdaq Global Select Market under the ticker symbol “TMCI”.
How many bunion surgeries are performed annually in the United States?
An estimated 450,000 surgical bunion procedures are performed in the United States each year, representing a market opportunity exceeding $2.3 billion. Approximately 1.1 million total candidates seek surgical solutions annually out of 67 million Americans affected by bunions.
What new products has Treace introduced to treat less severe bunions?
To address mild to moderate bunions and surgeon preferences for minimally invasive options, Treace introduced the Nanoplasty® 3D Minimally Invasive System (utilizing a titanium intramedullary implant through a 1.5 cm side incision) and the Percuplasty™ Percutaneous 3D System (designed for percutaneous “poke-hole” incisions), alongside the SpeedMTP® System for great toe fusions.
Where are the principal operations and manufacturing located?
Treace Medical Concepts is headquartered in Ponte Vedra, Florida, where it maintains its primary executive offices, research and development, and light assembly facilities. The company relies on third-party contract manufacturing partners located within the United States to produce its medical devices and single-use instruments.